CM
MRVI icon

Caption Management’s Maravai LifeSciences MRVI Stock Holding History

Caption Management’s Portfolio MRVI Stock Details MRVI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-500,000
Closed -$1.1M – 1725
2025
Q1 		$1.1M Buy
+500,000
New +$1.98M 0.01% 879

Other funds holding MRVI

GL
GTCR LLC Chicago, Illinois $3.78B AUM 27.82% 1-Year Est. Return
1WCM
12 West Capital Management New York $592M AUM 40.75% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
Mackenzie Financial
Mackenzie Financial Toronto Ontario, Ontario, Canada $83.3B AUM 31.19% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
MFS
Mirabella Financial Services London, United Kingdom $1.06B AUM 19.83% 1-Year Est. Return
PD
Point72 (DIFC) Dubai, United Arab Emirates $1.53B AUM 15.83% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Caption Management's MRVI Position: Q2 2025 in Review

Caption Management sold out of Maravai LifeSciences (MRVI) in Q2 2025, closing a stake of 272,486 shares — an estimated $602K sold.

Caption Management first reported a position in MRVI in Q2 2023 and held it in 2 quarters. The position peaked at $602K in Q1 2025. 150 funds tracked by Wall St. Rank hold MRVI as of Q2 2025.

  • Caption Management reported no remaining Maravai LifeSciences position as of Q2 2025 after selling out during the quarter.
  • Caption Management sold 272,486 Maravai LifeSciences shares in Q2 2025, an estimated $602K.
  • Caption Management first reported a position in Maravai LifeSciences in Q2 2023 and held it in 2 quarters.
  • Caption Management's Maravai LifeSciences position peaked at $602K in Q1 2025.
  • 150 funds tracked by Wall St. Rank held Maravai LifeSciences as of Q2 2025.

Based on Caption Management's 13F filing for Q2 2025, filed 14 Aug 2025.